Safety Alert

# Title Type of news Date Link of news
220 Safety Signals Identified by SFDA (July - September) 2025 Signal
219 Safety Signal of Cytarabine and the Risk of Palmar plantar erythrodysaesthesia syndrome Signal
218 Safety Signal of Adalimumab and the Risk of Osteonecrosis Signal
217 Safety Signal of Lenvatinib and the Risk of Tumour lysis syndrome Signal
216 Safety Signal of Onasemnogene abeparvovec and the Risk of Hypercalcaemia Signal
215 Safety Signal of Adalimumab and the Risk of Antiphospholipid syndrome Signal
214 Safety Signal of Atorvastatin and the Risk of Anxiety Signal
213 Safety Signal of Dasabuvir and the Risk of Increased appetite Signal
212 Safety Signal of Risankizumab and the Risk of Neutropenia Signal
211 Safety Signal of Sorafenib and the Risk of Multiple Organ Dysfunction Syndrome Signal
Displaying 1 - 10 of 222